A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial of lemborexant in adults with insomnia disorder.
Wei-Feng Mi, Dan Wen, Lijun Xu, Jiyang Pan, Ping Gu, Changhong Wang, Jiyou Tang, Li Zhang, Chun-Feng Liu, Chengmei Yuan, Hanqiao Wang, Naoto Yamakawa, Takao Takase, Margaret Moline, Lin Lu
Sleep Med 139 108722
摘要
摘要
INTRODUCTION: This study evaluated the efficacy and safety of lemborexant (LEM), a dual orexin-receptor antagonist, in participants with insomnia disorder in China. METHODS: E2006-J086-311 (Study 311; NCT04549168), a 1-month, multicenter, randomized, double-blind, placebo (PBO)-controlled, parallel-group study, enrolled adults (≥18 years) with insomnia disorder in China. Pairs of polysomnograms were conducted during a 7-day PBO run-in period (baseline), after the first 2 doses of LEM 10 mg (LEM10) or PBO, and after the last 2 doses at the end of 1 month of treatment. Objective sleep parameter assessments included latency to persistent sleep (LPS; primary endpoint) and secondary endpoints of sleep efficiency, wake after sleep onset (WASO), and total sleep time (TST; exploratory endpoint). Safety data were collected. RESULTS: Among 194 participants randomized (PBO, n = 100; LEM10, n = 94), the median age was approximately 42 years; most participants were female (PBO: 74.0 %; LEM10: 61.3 %). Following 1 month of treatment, mean (standard deviation [SD]) decreases from baseline in LPS were larger (improved) for the LEM10 treatment group (-39.47 min [46.147 min]) versus PBO (-21.71 min [42.809 min]; post hoc Box-Cox transformation, p = 0.0096). LEM10 demonstrated larger and statistically significant increases from baseline (improvements) in sleep efficiency (p < 0.0001) and TST (p < 0.0001) and significant decreases from baseline (improvement) in WASO (p = 0.0002) versus PBO and was well-tolerated. No new safety signals with LEM were observed in the current study compared with the known safety profile. CONCLUSIONS: LEM may be an important potential treatment option for patients with insomnia in China. TRIAL REGISTRATION: ClinicalTrials.gov identifier (first submitted on 09-09-2020): NCT04549168; Study protocol and statistical analysis plan may be accessed at: https://clinicaltrials.gov/study/NCT04549168.
KM 提取结果
0 个 Figure · 0 个 KM 面板